The share price of USA-based Bellicum Pharmaceuticals (Nasdaq:BLCM) increased by 2.5% to $16.98 on Tuesday morning after its expanded cell therapy collaboration with a European pediatric research center and hospital was announced.
Bellicum, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan-inherited blood disorders, is to develop CAR T and TCR product candidates that incorporate its control switch technology, CaspaCIDe, in the collaboration with Italy’s Ospedale Pediatrico Bambino Gesù (OPBG).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze